AbbVie Inc.
www.abbvie.com
Latest From AbbVie Inc.
J&J's Tremfya Gets Its Blockbuster Wings
The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company to raise guidance for the year.
Daiichi Sankyo’s AML Drug Among Nine CHMP Hopefuls
Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?
Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe
Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
Genentech Builds Case For Rituxan In Pemphigus With Comparator Study Data
Genentech reports that Rituxan yields better results over 52 weeks in pemphigus patients than off-label use of CellCept. Principia, meanwhile, unveils positive Phase II data for its pemphigus candidate.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
- AbbVie Inc.
- Senior Management
-
Richard A Gonzalez, Chmn. & CEO
Robert A Michael, EVP, CFO
Michael E Servino, MD, Pres.
Carlos Alban, Chief Commercial Officer - Contact Info
-
AbbVie Inc.
Phone: (847) 937-6100
1 N. Waukegan Rd.
North Chicago, IL 60064
USA
Advertisement
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice